Physician profile
Michael G Dunn
NPI 1780672592
$69,966.67
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $168 · 2021: $25.70.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $40,039.08 | 2019 | |
| Biogen, INC. | $16,065.24 | 2019 | |
| Genentech USA, INC. | $6,828.99 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $3,258.01 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $447.78 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $410.09 | 2019 | |
| Lundbeck LLC | $249.98 | 2019 | |
| Emd Serono, INC. | $221.67 | 2019 | |
| Allergan, INC. | $219.61 | 2019 | |
| Mallinckrodt Enterprises LLC | $209.88 | 2019 | |
| Amgen INC. | $184.60 | 2019 | |
| Jazz Pharmaceuticals INC. | $178.36 | 2019 | |
| Acorda Therapeutics, INC | $166.14 | 2019 | |
| Merz North America, INC. | $159.45 | 2019 | |
| Lilly USA, LLC | $150.47 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $139.37 | 2019 | |
| Sunovion Pharmaceuticals INC. | $132.13 | 2019 | |
| Neurocrine Biosciences, INC. | $120.86 | 2019 | |
| Grifols USA, LLC | $109.32 | 2019 | |
| Csl Behring | $93.27 | 2019 | |
| Ucb, INC. | $73.47 | 2019 | |
| Promius Pharma LLC | $58.40 | 2019 | |
| Abbvie INC. | $54.47 | 2019 | |
| Ge Healthcare | $48.86 | 2019-2020 | |
| Zyla Life Sciences, INC. | $47.84 | 2019 | |
| Livanova USA, INC. | $47.80 | 2019 | |
| Mdd US Operations, LLC | $44.43 | 2019 | |
| Upsher-Smith Laboratories LLC | $40.95 | 2019 | |
| Arbor Pharmaceuticals, INC. | $40.64 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.19 | 2019 | |
| Tanabe Pharma America, INC. | $22.05 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.93 | 2019 | |
| Akcea Therapeutics, INC. | $13.93 | 2019 | |
| Adamas Pharmaceuticals, INC. | $12.76 | 2019 | |
| Celgene Corporation | $11.54 | 2019 | |
| Pfizer INC. | $11.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.